Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (271-280 of 386) with videos related to

Pageof 39
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1997
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory StandardsJ H Rex, M A Pfaller, J N Galgiani, et al.
The Journal of Molecular Diagnostics : JMD|August 9, 2020
Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue SamplesWalead Ebrahimizadeh, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
The Lancet. Oncology|August 10, 2024
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trialLinda J Williams, Ian H Kunkler, Karen J Taylor, et al.
Breast Cancer Research and Treatment|October 14, 2010
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative studyE J Macaskill, J M S Bartlett, V S Sabine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Breast Cancer Research : BCR|December 16, 2022
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom studyDennis C Sgroi, Kai Treuner, Yi Zhang, et al.
Breast Cancer Research and Treatment|February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancerS Irshad, C Gillett, S E Pinder, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
The Journal of Pathology|March 21, 2012
Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progressionMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
Pageof 39

Showing results (271-280 of 386) with videos related to

Sort By:
Pageof 39
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1997
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory StandardsJ H Rex, M A Pfaller, J N Galgiani, et al.
The Journal of Molecular Diagnostics : JMD|August 9, 2020
Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue SamplesWalead Ebrahimizadeh, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
The Lancet. Oncology|August 10, 2024
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trialLinda J Williams, Ian H Kunkler, Karen J Taylor, et al.
Breast Cancer Research and Treatment|October 14, 2010
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative studyE J Macaskill, J M S Bartlett, V S Sabine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Breast Cancer Research : BCR|December 16, 2022
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom studyDennis C Sgroi, Kai Treuner, Yi Zhang, et al.
Breast Cancer Research and Treatment|February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancerS Irshad, C Gillett, S E Pinder, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
The Journal of Pathology|March 21, 2012
Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progressionMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
Pageof 39